GRAL241220C20000
- 2.30
- +1.06+85.48%
Grail Newsroom
Express News | Golden Grail Beverages Announces the Acquisition of Updc Beverages
Golden Grail Beverages Announces the Acquisition of UPDC Beverages
World's Biggest Hedge Fund Flags the 'Holy Grail' That May Shield Investors If U.S. Stock Rally Crumbles
Liom Cracks "Holy Grail" of Non-Invasive Glucose Monitoring and Secures USD >25m in Funding Kickstarting Its Series A
Express News | Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Grail 1st-Mover Advantage Faces Regulatory Hurdles in Multi-Cancer Detection, Morgan Stanley Says
GRAIL Analyst Ratings
Morgan Stanley Initiates GRAIL at Equalweight With $16 Price Target
Balanced Risk/Reward Scenario: Hold Rating for GRAIL Inc Amid Regulatory and Financial Challenges
Grail Initiated With an Equal Weight at Morgan Stanley
Institutional Investors in GRAIL, Inc. (NASDAQ:GRAL) Have Had a Wonderful Week After Share Price Increased 12%
Golden Grail Beverages Cancels Convertible Debt to Reduce Dilution
Grail Insider Sold Shares Worth $426,937, According to a Recent SEC Filing
GRAIL to Participate in Upcoming Investor Conferences
Golden Grail Beverages CEO Shares Global Vision in New Interview With SmallCapVoice.com
Grail Tests First Patient for TROPION-Lung12 Phase 3 Study
Express News | Grail Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Wolfe Research Initiates Grail(GRAL.US) With Hold Rating